Dr. Ruben Mesa, director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discussed the benefits of Fedratinib (Inrebic) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.
